PeptiDream Inc.
Fiscal Year Ending December 2026 Q3 Financial Summary〔IFRS〕(Consolidated)
For Q3 of the fiscal year ending December 2026, consolidated revenue was 14,820 million yen (YoY +15.3%), Core operating loss was -2,804 million yen. Full-year revenue forecast remains 32,000 million yen, Core operating profit 4,600 million yen. Treasury shares at period-end: 1,442,676 shares. No dividend forecast; results disclosed on an IFRS basis.
Key Figures
- Revenue: 14,820 million yen (YoY for same quarter +15.3%)
- Operating Loss: -2,867 million yen
- Net Income Attributable to Owners of Parent (Quarter): -2,362 million yen
AI要約
Key Points of Financial Results
This financial summary discloses PeptiDream Inc.'s consolidated IFRS results for Q3 of the fiscal year ending December 2026. Revenue was 14,820 million yen, an increase of 15.3% year-over-year, but Core operating profit was a loss of -2,804 million yen and operating profit was a loss of -2,867 million yen. The dividend forecast remains 0 yen at this time with no change. Shares outstanding at period-end were 130,010,400 shares, and treasury shares were 1,442,676 shares.
Outlook and Factors
The full-year forecast indicates revenue of 32,000 million yen, Core operating profit of 4,600 million yen, and net income of 3,000 million yen, but as noted in the financial summary, attention should be paid to differences between Core-adjusted figures and IFRS figures including one-off items. As recently announced, there is no dividend and no earnings presentation will be held.
Revenue Trend
Core Operating Profit Trend
Segment Revenue Breakdown
Operating Loss Margin
PeptiDream Inc.
Company overview · Stock price · Financial data · All IR
